Full-Time

Senior Manager

Instructional Design and Labeling Operations

Updated on 8/24/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$148.7k - $201.2k/yr

+ Annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

Hybrid

Flex commuter hybrid work arrangement.

Bachelor's, Master's, PhD, Associate's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Six Sigma

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 2 years of relevant regulated labeling, medical device, combination product, instructional design, Human Factors, design operations, process improvement, product development, quality, or related experience; or a master's degree and 6 years; or a bachelor's degree and 8 years; or an associate's degree and 10 years; or a high school diploma/GED and 12 years.
  • At least 2 years of experience directly managing people and/or leading teams, projects, programs, or directing resource allocation.
  • Experience in regulated medical product labeling, artwork, packaging, Human Factors, medical device, pharmaceutical, biotechnology, combination product, quality, or design operations.
  • Experience improving processes, implementing standard operating procedures, developing templates and checklists, defining role clarity, and scaling functional operations.
  • Experience owning or governing controlled procedures, including implementation, adherence, training, inspection readiness, and continuous improvement.
  • Knowledge of instructions for use, instructional materials, labeling and artwork development, Human Factors study materials, Health Authority submission support, or regulated document workflows.
  • Experience with document management systems, review workflows, source text and artwork alignment, traceability, and audit-ready documentation.
  • Vendor management experience, including defining expectations, managing deliverables, monitoring performance, and resolving quality or timeline issues.
  • Ability to manage multiple priorities, identify risks, escalate appropriately, and drive decisions in a matrixed environment.
Responsibilities
  • Lead, coach, and develop a team of Instructional Design Engineers.
  • Clarify role expectations, support development plans, create growth opportunities, and help team members build differentiated career paths.
  • Build a high-performing team culture grounded in accountability, collaboration, learning, quality, operational discipline, and customer focus.
  • Manage team priorities, workload, capacity, onboarding, performance, development, and resource allocation.
  • Oversee external workers and contractors, including onboarding, work assignment, deliverable expectations, execution quality, and integration into team workflows.
  • Lead the Instructional Design and Labeling Operations function within Customer Experience and Design.
  • Translate portfolio needs, Human Factors milestones, labeling deliverables, study timelines, submission needs, and business priorities into executable team plans.
  • Monitor workload, workflow health, quality trends, cycle times, risks, rework drivers, and delivery commitments.
  • Strengthen the operating model, including role clarity, decision rights, intake, prioritization, escalation, metrics, and cross-functional handoffs.
  • Ensure the team's work supports improved patient learning materials, usability, complaint reduction, and customer experience outcomes.
  • Lead process improvement across the Instructions for Use and Native Artwork Files lifecycle, including strategy, creation, revision, review cycles, Human Factors study support, source text alignment, submission support, vendor coordination, and launch readiness.
  • Develop, maintain, and improve templates, checklists, standards, process maps, training materials, metrics, and review expectations.
  • Identify and resolve process gaps, handoff inefficiencies, documentation risks, role clarity issues, recurring workflow pain points, and compliance vulnerabilities.
  • Provide leadership oversight for Instructions for Use, instructional artwork, illustrations, Native Artwork Files, study stimuli, and related deliverables.
  • Ensure deliverables address user needs, usability principles, labeling requirements, regulatory expectations, documentation traceability, and quality standards.
  • Oversee Native Artwork Files strategy, artwork creation, review cycles, source text alignment, print readiness, study stimuli preparation, vendor coordination, and submission readiness.
  • Ensure quality checks, review discipline, documentation, and inspection practices are in place before deliverables proceed to formal review, study use, or submission.
  • Support issue resolution and decision-making when design, usability, labeling, regulatory, packaging, artwork, quality, or operational considerations conflict.
  • Build partnerships with Human Factors, Regulatory Labeling, Packaging Engineering, Artwork Center, Systems Engineering, Quality, Final Product Teams, vendors, and other partners.
  • Represent Instructional Design and Labeling Operations in portfolio, program, governance, and process discussions.
  • Communicate priorities, risks, decisions, and tradeoffs to senior leaders and cross-functional stakeholders.
  • Influence across matrix teams to drive alignment, remove barriers, and maintain momentum.
  • Manage vendor and contractor relationships supporting execution, capacity, quality, specialized capability, print readiness, study support, and process reliability.
  • Ensure vendors and external partners understand applicable expectations, timelines, deliverable standards, documentation needs, and escalation pathways.
  • Ensure activities are performed and documented according to applicable procedures, standards, and regulatory expectations.
  • Promote traceability of inputs, decisions, reviews, revisions, approvals, study support activities, and submission-related deliverables.
  • Support audit readiness, inspection readiness, and responses to Health Authority questions or feedback.
  • Drive quality ownership, right-first-time execution, and continuous learning from errors, rework, study outcomes, stakeholder feedback, and process metrics.
Desired Qualifications
  • Demonstrated people leadership experience, including coaching, performance management, career development, workload management, and building high-performing teams.
  • Experience leading employees, external workers, contractors, vendors, or matrixed contributors in a regulated or quality-sensitive environment.
  • Combination product experience; broader regulated medical space labeling or artwork experience may be suitable.
  • Strong cross-functional leadership and influencing skills across technical, regulatory, quality, operational, and design perspectives.
  • Strong written, verbal, facilitation, and executive communication skills.
  • Ability to translate customer, patient, user, and business needs into practical operational improvements.
  • Lean, Six Sigma, process excellence, change management, or operational excellence experience.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.